Journal Club Review: 6-Month Guselkumab Effectiveness in PsA (Real-World CorEvitas Data)

Join Jessica Farrell, PharmD, clinical pharmacist at Albany Medical Center’s Division of Rheumatology and faculty at Albany College of Pharmacy and Health Sciences, as she delves into real-world evidence on Guselkumab for psoriatic arthritis (PsA). In this session, she breaks down findings from a study published in Rheumatology and Therapy (August 2023) by Dr. Miscol, which evaluates the six-month persistence and multi-domain effectiveness of Guselkumab using data from the CorEvitas PsA and Spondyloarthritis Registry.The study followed PsA patients receiving Guselkumab 100 mg at weeks 0, 4, and then every 8 weeks, assessing disease activity at baseline and again at six months. Key measures included the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score, physician global assessment (PGA), patient-reported pain, and psoriasis severity (BSA). Notably, 80% of patients persisted with treatment through six months, showing statistically significant improvements across multiple disease domains. With an average disease duration of 14 years, most participants had prior biologic exposure, making these findings particularly relevant to real-world clinical practice.Jessica highlights the value of registry data in validating clinical trial results, providing confidence that Guselkumab’s benefits translate beyond controlled study environments into everyday patient care. Real-world evidence helps clinicians set patient expectations and refine treatment strategies for optimal outcomes.For more expert insights on RA remission, Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.